Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.
Marker Therapeutics, Inc. (Nasdaq: MRKR) is a Houston, Texas-based, clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. This news page aggregates company press releases and third-party coverage related to MRKR, with a focus on clinical data, research milestones, and corporate developments.
Investors and followers of MRKR can review updates on the company’s lead program, MT-601, a MAR-T cell product being evaluated in the Phase 1 APOLLO trial for patients with relapsed or refractory lymphoma who have failed or are not candidates for anti-CD19 CAR-T cell therapy. News items include reported objective response rates, safety findings such as the absence of dose-limiting toxicities and ICANS in dose escalation cohorts, and progress into dose expansion in diffuse large B cell lymphoma.
Coverage also highlights Marker’s expansion into additional indications, including a pancreatic cancer program supported by non-dilutive funding and an Off-the-Shelf MAR-T initiative, MT-401-OTS, in the RAPID trial for relapsed acute myeloid leukemia or myelodysplastic syndromes. Readers will find announcements on first-patient dosing, early safety observations, and scientific insights such as the impact of lymphodepletion on MAR-T cell expansion and persistence.
Beyond clinical results, MRKR news includes financial updates, grant awards from U.S. state and federal agencies, collaborations such as the cGMP manufacturing agreement with Cellipont Bioservices for MT-601, participation in investor conferences, and changes in corporate governance and auditors. This page is a resource for tracking how Marker’s MAR-T platform and pipeline evolve over time.
Marker Therapeutics (Nasdaq: MRKR) reported 2025 corporate and financial results on March 18, 2026. Key clinical highlights include a 66% objective response rate in relapsed non-Hodgkin lymphoma with 50% complete responses in the Phase 1 APOLLO update.
Other items: Nature Medicine pancreatic data showing up to 84.6% disease control, manufacturing collaboration with Cellipont, Board appointment of Kathryn Penkus Corzo, and year-end cash of $17 million (funding through Q4 2026 per the company). 2025 net loss was $12.2 million.
Marker Therapeutics (NASDAQ: MRKR) announced CEO Dr. Juan Vera will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, from 8:00–8:30 a.m. EST. The event is virtual; a webcast will be available via the company’s Investor Relations “Events and Presentations” page.
Management will hold one-on-one investor meetings to discuss progress across Marker’s Multi-Antigen Recognizing (MAR) T cell platform.
Marker Therapeutics (Nasdaq: MRKR) highlighted Baylor College of Medicine’s TACTOPS Phase 1/2 pancreatic cancer study on Good Morning America on Jan 22, 2026, and the research was recently published in Nature Medicine. The Baylor study reported a favorable safety profile and up to a 84.6% disease control rate in Arm A when Multi-Antigen Targeted T cells were combined with frontline chemotherapy. In Arm A the median duration of response was 7.5 months and median overall survival was 14.1 months; infused T cells were detected up to 12 months post-treatment. Marker plans a company-sponsored trial (NCT06549751) with expanded antigen targets, higher cell doses and lymphodepletion, has SBIR and CPRIT funding, and anticipates clinical initiation in H1 2026.
Marker Therapeutics (Nasdaq: MRKR) announced publication of Baylor College of Medicine clinical data showing a favorable safety profile and an 84.6% disease control rate in Arm A when Multi-Antigen Targeted T cells were combined with frontline chemotherapy in pancreatic ductal adenocarcinoma.
Key metrics: median duration of response 7.5 months (range 3.5–16.6) for responders and median overall survival 14.1 months. Infused T cells persisted at detectable levels 12 months post-treatment and higher frequencies correlated with clinical response. Marker says it plans to start its pancreatic program in H1 2026 and has secured non-dilutive NIH SBIR and CPRIT funding to support the program.
Marker Therapeutics (NASDAQ: MRKR) reported Q3 2025 results and program updates on Nov 14, 2025. Key clinical highlights include a 66% objective response rate and 50% complete response rate for MT-601 in relapsed NHL from the Phase 1 APOLLO study (8/12 ORR; 6/12 CR), with five responses ≥6 months and three ≥12 months. No DLTs or ICANS observed. The company treated the first patient in its Off-the-Shelf RAPID study and signed a cGMP manufacturing collaboration with Cellipont. Marker raised approximately $10.0 million via ATM; cash and restricted cash totaled $19.0 million at 9/30/25, funding operations into Q3 2026 under current assumptions.
Marker Therapeutics (Nasdaq: MRKR) announced the appointment of Kathryn Penkus Corzo to its Board of Directors, effective November 1, 2025.
Ms. Penkus Corzo brings more than 30 years of biopharma leadership across R&D, clinical development, regulatory approvals, commercialization, and corporate strategy. She most recently served as President and COO at bit.bio and previously led oncology cell therapy development at Takeda Ventures, with senior roles at Sanofi Genzyme, Roche, Eli Lilly, and Syndax.
Company leadership said the appointment strengthens the board as Marker advances its lead asset MT-601 and the APOLLO program toward a potential pivotal study in patients with CAR-relapsed diffuse large B-cell lymphoma (DLBCL).
Marker Therapeutics (Nasdaq: MRKR) will present Phase 1 APOLLO data for MT-601 at the 67th ASH Annual Meeting, Dec 6-9, 2025 in Orlando.
Key results: in relapsed Non-Hodgkin lymphoma (NHL) patients ORR was 66% (8/12) with 50% CR; responses lasted 3–24 months with five patients ≥6 months and three >12 months. In Hodgkin lymphoma (HL) ORR was 78% (7/9) with 11% CR. No dose limiting toxicities or ICANS were reported; two participants had Grade 1 CRS. Company advanced to dose expansion at 400x10^6 cells in DLBCL post-CAR-T or CAR-T ineligible patients.
Marker Therapeutics (Nasdaq: MRKR) — Oct 6, 2025 announced the first patient was treated in the Phase 1 RAPID study testing MT-401, a multi-antigen recognizing (MAR) T cell off-the-shelf (OTS) product.
The first participant received the initial dose of 100x10^6 cells and was monitored for 28 days; the therapy was reported as well tolerated with no treatment-related adverse events. The OTS program initially targets AML and MDS and may expand to other indications. Marker said commercially sourced leukapheresis from healthy donors could enable treatment as fast as 72 hours. The program is supported by non-dilutive funding from the FDA, NIH SBIR, and CPRIT.
Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Dr. Juan Vera will lead a fireside chat on September 10, 2025, from 12:30 to 1:00 p.m. EDT at the Lotte New York Palace Hotel. The management team will also conduct one-on-one meetings with investors to discuss their MAR T cell platform and clinical developments, including updates from the Phase 1 APOLLO study.
Investors can access the webcast through Marker's Investor Relations website under "Events and Presentations".
Marker Therapeutics (NASDAQ:MRKR) has reported encouraging results from its Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing T cell product, for treating relapsed lymphoma. The study demonstrated a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete response.
The trial included 24 B-cell lymphoma patients across 7 U.S. clinical sites, with doses ranging from 100x106–400x106 cells. Notable outcomes include 78% objective response rate in Hodgkin Lymphoma patients and durable responses lasting 3-24 months. The treatment showed a favorable safety profile with no dose-limiting toxicities or serious adverse events.
The company is advancing to the dose expansion phase, investigating MT-601 at the maximum dose of 400x106 cells in DLBCL patients who have relapsed after or are ineligible for CAR-T therapy.